Skip to Content

Target: Rogue Immune Cells

DNA-derived vaccine advances on MS.
September 1, 2003

Drugs for autoimmune diseases like multiple sclerosis, type 1 diabetes, and rheumatoid arthritis provide relief from symptoms but don’t address causes. Researchers now hope to change that with an emerging class of vaccines made from DNA that shut down the immune cells that go awry in these diseases. Early results have been so promising that human trials for the first treatment-a multiple sclerosis therapy that made paralyzed mice walk again-will begin early next year.

In MS patients, rogue immune cells attack the nerve covering called the myelin sheath, leading to numbness, weakness, cognitive problems, and eventually paralysis. There’s no existing cure; a leading drug, called beta-interferon, regulates the immune system to reduce the severity of attacks but can carry severe side effects. “Treatments today for these types of autoimmune diseases are basically blunt instruments,” says John Walker, CEO of Bayhill Therapeutics, the Palo Alto, CA, startup developing these DNA vaccines. “We’re interested in taking much more of a rifle-shot approach.”

Two engineered DNA molecules make up the vaccine; both are taken up by specialized “first responder” immune cells, which are thus transformed into MS-fighting machines. One DNA molecule encodes a protein found in the myelin sheath; the first-responders make this protein, which acts as bait for the rogue immune cells. Once this trap is sprung, the second DNA molecule goes to work. It encodes a protein that switches the rogue cells from a destructive mode to a protective mode.

Lawrence Steinman, the Stanford University Medical Center immunologist and neurologist who developed the approach and cofounded Bayhill, says the strategy has dramatically reduced the severity of the disease in mice-and even made paralyzed mice walk again. “There isn’t a mouse we haven’t cured,” Steinman says. “Now the issue is, can we translate this into man?”

With 350,000 people suffering from MS in the United States alone, that is a critical question. To begin answering it, the company has raised $14.5 million in its first round of financing and plans to begin human trials of the MS vaccine in early 2004. If all goes well, a vaccine could reach patients in about seven years.

Once the technology is proved in humans, Bayhill plans to develop treatments for other autoimmune diseases. Indeed, the same basic approach has met with success in mouse models of rheumatoid arthritis and type 1 diabetes. New studies are testing whether it may even be possible to reverse existing joint damage. Vijay Kuchroo, a neurologist at Harvard Medical School, believes DNA vaccination “has broad applications” for autoimmune diseases. “I think it has a great future,” he says. While that remains to be seen, the root causes of autoimmune diseases are in researchers’ rifle sights.

Keep Reading

Most Popular

individual aging affects covid outcomes concept
individual aging affects covid outcomes concept

Anti-aging drugs are being tested as a way to treat covid

Drugs that rejuvenate our immune systems and make us biologically younger could help protect us from the disease’s worst effects.

close up of baby with a bottle
close up of baby with a bottle

The baby formula shortage has birthed a shady online marketplace

Desperate parents just want to feed their babies. They’re having to contend with misinformation, price gouging, and scams along the way.

"Olive Garden" NFTs concept
"Olive Garden" NFTs concept

I tried to buy an Olive Garden NFT. All I got was heartburn.

Our newest issue spells out what you need to know about the dizzying world of digital money.

Stay connected

Illustration by Rose WongIllustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.